Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1409 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Use of abatacept, a targeted DMARD (tDMARD), in patients with RA has shown to improve whole-body insulin sensitivity and reduce HbA1c levels.1 Comparative evidence…
Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting
Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Katie Bechman¹, Anuoluwapo Oke ², Mark Yates ³, Sam Norton ³, Elaine Denderson ⁴, Andrew Cope ⁵ and James Galloway ², ¹Kings College London, London, England, United Kingdom, ²Kings College London, London, United Kingdom, ³Kings College London, London, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ⁵Academic Rheumatology, King's College London, London, United Kingdom
Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
Abstract Number: 1891 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis
Priyanka Iyer ¹, Yubo Gao ², Saket Girotra ², Jeffrey Curtis ³, Mary Vaughan-Sarrazin ⁴ and Namrata Singh⁴, ¹University of Iowa, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa city, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Iowa, Iowa City
Background/Purpose: Hydroxychloroquine (HCQ) has known immunomodulatory effects and mechanistic actions that may provide cardioprotective effects. To date, cardiovascular (CV) outcomes in elderly patients receiving HCQ…
Abstract Number: 2006 • 2019 ACR/ARP Annual Meeting
Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis
Dong Woo Han ¹, Yong Seok Choi ¹, You-Jung Ha², Eun Hye Park ², Eun Ha Kang ², Yeong-Wook Song ³ and Yun Jong Lee ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Pyruvate kinase M2 (PKM2), one of glycolytic enzymes, is an emerging molecule that plays significant roles in tumor growth as well as inflammatory process.…
Abstract Number: 2207 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density and Microarchitecture Among Chinese Patients with Rheumatoid Arthritis
Shangyi Jin¹, Evelyn Hsieh ², Weibo Xia ³, Mengtao Li ⁴, Qian Wang ¹ and Xiaofeng Zeng ¹, ¹Department of Rheumatology, Key Laboratory of Rheumatology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, People’s Republic of China, Beijing, Beijing, China (People's Republic), ²Section of Rheumatology, Yale School of Medicine, NewHaven, CT, ³Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China (People's Republic), ⁴Dept. of Rheumatology, Peking Union Medical College Hospital (West Campus), Beijing, China, Beijing, China (People's Republic)
Background/Purpose: To evaluate alterations of bone mineral density and microarchitecture in patients with rheumatoid arthritis (RA). We also aimed to identify potential factors associated with…
Abstract Number: 2303 • 2019 ACR/ARP Annual Meeting
Emotional and Social Determinants of Health Increase Office Communication for Patients with Rheumatoid Arthritis
Dana DiRenzo¹, Michael Wu ², Thomas Grader-Beck ², Susan J. Bartlett ³ and Clifton Bingham ¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³McGill University, Montreal, QC, Canada
Background/Purpose: In RA patients, anxiety and depression are associated with higher disease activity and worse outcomes. We hypothesized that in RA patients, poorer mental health…
Abstract Number: 2325 • 2019 ACR/ARP Annual Meeting
High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles
Brian Andonian¹, David Bartlett ¹, Deborah Muoio ¹, Timothy Koves ¹, Olga Ilkayeva ¹, Andrew Hoselton ¹, Megan Reaves ¹, William Kraus ¹ and Kim Huffman ¹, ¹Duke University, Durham, NC
Background/Purpose: Patients with rheumatoid arthritis (RA) are at greater risk for cardiometabolic disease and early death. It is unclear if current anti-inflammatory pharmacotherapies alone are…
Abstract Number: 2343 • 2019 ACR/ARP Annual Meeting
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Shinji Watanabe¹, Takahisa Gono ¹, Ryosuke Fukue ¹, Seiji Kobayashi ¹, Yuichiro Shirai ², Mitsuhiro Takeno ³ and Masataka Kuwana ², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ³Nippon Medical School, Tokyo, Japan
Background/Purpose: Pulmonary complication is one of the leading causes of mortality in patients with rheumatoid arthritis (RA). Pre-existing lung disease is known as a risk…
Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…
Abstract Number: 2397 • 2019 ACR/ARP Annual Meeting
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
Yoshinobu Koyama¹, Akemi Senoo ², Kaho Otsuki ³, Yoshiharu Sato ⁴, Mari Yamaguchi ² and Toshie Higuchi ¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, ²Division of Dermatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, ³Center for Autoimmune Diseases, Division of Rheumatology, Okayama, Japan, ⁴DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse…
Abstract Number: 2806 • 2019 ACR/ARP Annual Meeting
Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis
Anna Montgomery ¹, Shang-Yang Chen¹, Philip Homan ¹, Gaurav Gadhvi ¹, Deborah Winter ² and Harris Perlman ², ¹Northwestern University, Chicago, ²Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago
Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). However, their heterogeneity remains poorly characterized.Methods:…
Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark¹, Jon Einarsson ², Jan-Åke Nilsson ³ and Meliha Kapetanovic ², ¹Lund University, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ³Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
Abstract Number: 42 • 2019 ACR/ARP Annual Meeting
Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
Sheila Arvikar¹, Hatice Hasturk ², Klemen Strle ¹, Marcy Bolster ¹, Deborah Collier ¹, Alpdogan Kantarci ² and Allen Steere ¹, ¹Massachusetts General Hospital, Boston, MA, ²Forsyth, Cambridge, MA
Background/Purpose: Periodontitis and immune responses to periodontal pathogens such as Porphyromonas gingivalis (Pg) are associated with rheumatoid arthritis (RA) but the mechanisms underlying these connections…
Abstract Number: 177 • 2019 ACR/ARP Annual Meeting
Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal
Mariana Luís¹, Salomé Garcia ², Francisca Guimarães ³, Manuel António ⁴, Ana Fernandes ⁵, Filipe Araújo ⁶, Rita Cunha ⁷, Maura Couto ⁸, Ana Pinto ⁹, Lígia Silva ¹⁰, Margarida Cruz ¹¹, Jose Pereira da Silva ¹² and Catia Duarte ¹³, ¹Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ²Centro Hospitalar São João, Porto, Portugal, ³Centro Hospitalar do Alto Minho, Ponte de Lima, Portugal, ⁴Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Centro Hospitalar do Algarve, Faro, Portugal, ⁶Hospital Ortopédico de Sant’Ana, Lisboa, Portugal, ⁷Centro Hospitalar Baixo Vouga, Aveiro, Portugal, ⁸Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ⁹Unidade Local de Saúde da Guarda, Guarda, Portugal, ¹⁰Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ¹¹Centro Hospitalar do Oeste, Caldas da Rainha, Portugal, ¹²Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, ¹³Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal
Background/Purpose: Work disability is a common consequence of Rheumatoid Arthritis (RA) with economic implications for both the patient and society. Scarce information is available on…
Abstract Number: 248 • 2019 ACR/ARP Annual Meeting
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Caroline Swift ¹, Yvonne Viteri², Gail Bridges ³, Mary Dorholt ⁴ and Monal Kohli ⁵, ¹Express Scripts, St. Louis, MO, ²Accredo, Northvale, NJ, ³Accredo, Memphis, TN, ⁴Accredo, Maple Grove, MN, ⁵Express Scripts, Franklin Lakes, NJ
Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].